Clinical and electrophysiological characteristics of women with X-linked Charcot-Marie-Tooth disease.
CMTX
Charcot-Marie-Tooth
clinical trial
connexine 32
hereditary peripheral neuropathy
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
07
06
2023
received:
24
01
2023
accepted:
15
06
2023
medline:
8
9
2023
pubmed:
19
6
2023
entrez:
19
6
2023
Statut:
ppublish
Résumé
X-Linked Charcot-Marie-Tooth disease type 1 (CMTX1) is characterized by gender differences in clinical severity. Women are usually clinically affected later and less severely than men. However, their clinical presentation appears to be heterogenous. Our aim was to extend the phenotypic description in a large series of women with CMTX1. We retrospectively evaluated 263 patients with CMTX1 from 11 French reference centers. Demographic, clinical, and nerve conduction data were collected. The severity was assessed by CMT Examination Score (CMTES) and Overall Neuropathy Limitations Scale (ONLS) scores. We looked for asymmetrical strength, heterogeneous motor nerve conduction velocity (MNCV), and motor conduction blocks (CB). The study included 137 women and 126 men from 151 families. Women had significantly more asymmetric motor deficits and MNCV than men. Women with an age of onset after 19 years were milder. Two groups of women were identified after 48 years of age. The first group represented 55%, with women progressing as severely as men, however, with a later onset age. The second group had mild or no symptoms. Some 39% of women had motor CB. Four women received intravenous immunoglobulin before being diagnosed with CMTX1. We identified two subgroups of women with CMTX1 who were over 48 years of age. Additionally, we have demonstrated that women with CMTX can exhibit an atypical clinical presentation, which may result in misdiagnosis. Therefore, in women presenting with chronic neuropathy, the presence of clinical asymmetry, heterogeneous MNCV, and/or motor CB should raise suspicion for X-linked CMT, particularly CMTX1, and be included in the differential diagnosis.
Sections du résumé
BACKGROUND
X-Linked Charcot-Marie-Tooth disease type 1 (CMTX1) is characterized by gender differences in clinical severity. Women are usually clinically affected later and less severely than men. However, their clinical presentation appears to be heterogenous. Our aim was to extend the phenotypic description in a large series of women with CMTX1.
METHODS
We retrospectively evaluated 263 patients with CMTX1 from 11 French reference centers. Demographic, clinical, and nerve conduction data were collected. The severity was assessed by CMT Examination Score (CMTES) and Overall Neuropathy Limitations Scale (ONLS) scores. We looked for asymmetrical strength, heterogeneous motor nerve conduction velocity (MNCV), and motor conduction blocks (CB).
RESULTS
The study included 137 women and 126 men from 151 families. Women had significantly more asymmetric motor deficits and MNCV than men. Women with an age of onset after 19 years were milder. Two groups of women were identified after 48 years of age. The first group represented 55%, with women progressing as severely as men, however, with a later onset age. The second group had mild or no symptoms. Some 39% of women had motor CB. Four women received intravenous immunoglobulin before being diagnosed with CMTX1.
CONCLUSIONS
We identified two subgroups of women with CMTX1 who were over 48 years of age. Additionally, we have demonstrated that women with CMTX can exhibit an atypical clinical presentation, which may result in misdiagnosis. Therefore, in women presenting with chronic neuropathy, the presence of clinical asymmetry, heterogeneous MNCV, and/or motor CB should raise suspicion for X-linked CMT, particularly CMTX1, and be included in the differential diagnosis.
Substances chimiques
Connexins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3265-3276Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023 European Academy of Neurology.
Références
Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clin Genet. 1974;6(2):98-118.
Rossor AM, Polke JM, Houlden H, Reilly MM. Clinical implications of genetic advances in Charcot-Marie-Tooth disease. Nat Rev Neurol. 2013;9(10):562-571.
Fridman V, Bundy B, Reilly MM, et al. CMT subtypes and disease burden in patients enrolled in the inherited neuropathies consortium natural history study: a cross-sectional analysis. J Neurol Neurosurg Psychiatry. 2015;86(8):873-878.
Murphy SM, Laura M, Fawcett K, et al. Charcot-Marie-Tooth disease: frequency of genetic subtypes and guidelines for genetic testing. J Neurol Neurosurg Psychiatry. 2012;83(7):706-710.
Bergoffen J, Scherer SS, Wang S, et al. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science. 1993;262(5142):2039-2042.
Shy ME, Siskind C, Swan ER, et al. CMT1X phenotypes represent loss of GJB1 gene function. Neurology. 2007;68(11):849-855.
Bruzzone R, White TW, Paul DL. Connections with connexins: the molecular basis of direct intercellular signaling. Eur J Biochem. 1996;238(1):1-27.
Balice-Gordon RJ, Bone LJ, Scherer SS. Functional gap junctions in the Schwann cell myelin sheath. J Cell Biol. 1998;142(4):1095-1104.
Bihel F, Gess B, Fontés M. CMTX disorder and CamKinase. Front Cell Neurosci. 2016;10:49.
Rash JE, Yasumura T, Dudek FE, Nagy JI. Cell-specific expression of connexins and evidence of restricted gap junctional coupling between glial cells and between neurons. J Neurosci. 2001;21(6):1983-2000.
Yuan JH, Sakiyama Y, Hashiguchi A, et al. Genetic and phenotypic profile of 112 patients with X-linked Charcot-Marie-Tooth disease type 1. Eur J Neurol. 2018;25(12):1454-1461.
Al-Mateen M, Craig AK, Chance PF. The central nervous system phenotype of X-linked Charcot-Marie-Tooth disease: a transient disorder of children and young adults. J Child Neurol. 2014;29(3):342-348.
Hardy DI, Licht DJ, Vossough A, Kirschen MP. X-linked Charcot-Marie-Tooth disease presenting with stuttering stroke-like symptoms. Neuropediatrics. 2019;50(5):304-307.
Liang Y, Liu J, Cheng D, Wu Y, Mo L, Huang W. Recurrent episodes of reversible posterior leukoencephalopathy in three Chinese families with GJB1 mutations in X-linked Charcot-Marie-Tooth type 1 disease: cases report. BMC Neurol. 2019;19(1):325.
Tziakouri A, Natsiopoulos K, Kleopa KA, Michaelides C. Transient, recurrent central nervous system clinical manifestations of X-linked Charcot-Marie-Tooth disease presenting with very long latency periods between episodes: is prolonged sun exposure a provoking factor? Case Rep Neurol Med. 2020;2020:1-5.
Stancanelli C, Taioli F, Testi S, et al. Unusual features of central nervous system involvement in CMTX associated with a novel mutation of GJB1 gene. J Peripher Nerv Syst. 2012;17(4):407-411.
Vivekanandam V, Hoskote C, Rossor AM, Reilly MM. CNS phenotype in X linked Charcot-Marie-Tooth disease. J Neurol Neurosurg Psychiatry. 2019;90(9):1068.
Yang Q, Xiao X, Yuan Z, Jiao B, Liao X, Du J. Expansion of the phenotypic spectrum of X-linked Charcot-Marie-Tooth (CMT) disease. J Clin Neurosci. 2020;73:311-313.
Nicholson G, Nash J. Intermediate nerve conduction velocities define X-linked Charcot-Marie-Tooth neuropathy families. Neurology. 1993;43(12):2558-2564.
Panosyan FB, Laura M, Rossor AM, et al. Cross-sectional analysis of a large cohort with X-linked Charcot-Marie-Tooth disease (CMTX1). Neurology. 2017;89(9):927-935.
Birouk N, LeGuern E, Maisonobe T, et al. X-linked Charcot-Marie-Tooth disease with connexin 32 mutations: clinical and electrophysiologic study. Neurology. 1998;50(4):1074-1082.
Kleopa KA, Abrams CK, Scherer SS. How do mutations in GJB1 cause X-linked Charcot-Marie-Tooth disease? Brain Res. 2012;1487:198-205.
Dubourg O, Tardieu S, Birouk N, et al. Clinical, electrophysiological and molecular genetic characteristics of 93 patients with X-linked Charcot-Marie-Tooth disease. Brain J Neurol. 2001;124(Pt 10):1958-1967.
Siskind CE, Murphy SM, Ovens R, Polke J, Reilly MM, Shy ME. Phenotype expression in women with CMT1X. J Peripher Nerv Syst. 2011;16(2):102-107.
Shy ME, Blake J, Krajewski K, et al. Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology. 2005;64(7):1209-1214.
Graham RC. A modified peripheral neuropathy scale: the overall neuropathy limitations scale. J Neurol Neurosurg Psychiatry. 2006;77(8):973-976.
Murphy SM, Herrmann DN, McDermott MP, et al. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst. 2011;16(3):191-198.
van den Bergh PYK, Doorn PA, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-Second revision. J Peripher Nerv Syst. 2021;26(3):242-268.
Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain. 1980;103(2):259-280.
Nandedkar SD, Mansukhani K, More N, Sharma A, Chavan P. Revising nerve conduction reference limits. Muscle Nerve. 2021;64(1):99-103.
Hong YB, Park JM, Yu JS, et al. Clinical characterization and genetic analysis of Korean patients with X-linked Charcot-Marie--Tooth disease type 1. J Peripher Nerv Syst. 2017;22(3):172-181.
Lu YY, Lyu H, Jin SQ, et al. Clinical and genetic features of Chinese X-linked Charcot-Marie-Tooth type 1 disease. Chin Med J (Engl). 2017;130(9):1049-1054.
Gouvea SP, Tomaselli PJ, Barretto LS, et al. New novel mutations in Brazilian families with X-linked Charcot-Marie-Tooth disease. J Peripher Nerv Syst. 2019;24(2):207-212.
Koutsis G, Breza M, Velonakis G, et al. X linked Charcot-Marie-Tooth disease and multiple sclerosis: emerging evidence for an association. J Neurol Neurosurg Psychiatry. 2019;90(2):187-194.
Ayrignac X, Carra-Dalliere C, Menjot de Champfleur N, et al. Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients. Brain. 2015;138(2):284-292.
Burns J, Ouvrier R, Estilow T, et al. Symmetry of foot alignment and ankle flexibility in paediatric Charcot-Marie-Tooth disease. Clin Biomech. 2012;27(7):744-747.
Pelayo-Negro AL, Carr AS, Laura M, Skorupinska M, Reilly MM. An observational study of asymmetry in CMT1A. J Neurol Neurosurg Psychiatry. 2015;86(5):589-590.
Zito A, Davies MN, Tsai PC, et al. Heritability of skewed X-inactivation in female twins is tissue-specific and associated with age. Nat Commun. 2019;10(1):5339.
Gale RE, Wheadon H, Boulos P, Linch DC. Tissue specificity of X-chromosome inactivation patterns. Blood. 1994;83(10):2899-2905.
Gutierrez A, England JD, Sumner AJ, et al. Unusual electrophysiological findings in X-linked dominant Charcot-Marie-Tooth disease. Muscle Nerve. 2000;23(2):182-188.
Tabaraud F, Lagrange E, Sindou P, Vandenberghe A, Levy N, Vallat JM. Demyelinating X-linked Charcot-Marie-Tooth disease: unusual electrophysiological findings. Muscle Nerve. 1999;22(10):1442-1447.
Hahn AF, Bolton CF, White CM, et al. Genotype/phenotype correlations in X-linked dominant Charcot-Marie-Tooth disease. Ann N Y Acad Sci. 1999;883:366-382.
Scherer SS, Xu YT, Nelles E, Fischbeck K, Willecke K, Bone LJ. Connexin32-null mice develop demyelinating peripheral neuropathy. Glia. 1998;24(1):8-20.
Tan CC, Ainsworth PJ, Hahn AF, MacLeod PM. Novel mutations in the connexin 32 gene associated with X-linked Charcot-Marie tooth disease. Hum Mutat. 1996;7(2):167-171.
Lewis RA. The challenge of CMTX and connexin 32 mutations. Muscle Nerve. 2000;23(2):147-149.
Hauw F, Fargeot G, Adams D, et al. Charcot-Marie-Tooth disease misdiagnosed as chronic inflammatory demyelinating polyradiculoneuropathy: an international multicentric retrospective study. Eur J Neurol. 2021;28(9):2846-2854.
Bone LJ, Dahl N, Lensch MW, et al. New connexin32 mutations associated with X-linked Charcot-Marie-Tooth disease. Neurology. 1995;45(10):1863-1186.